Basic Information
TWINRIX VACCINE
INJECTION
Regulatory Information
SIN10932P
May 18, 1999
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07BC20
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 20 mcg/ml
Strength: 720 elisa units/ml
Detailed Information
Contraindications
**Contraindications** **Twinrix** should not be administered to subjects with known hypersensitivity to any constituent of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of **Twinrix** or the monovalent hepatitis A or hepatitis B vaccines. As with other vaccines, the administration of **Twinrix** should be postponed in subjects suffering from acute severe febrile illness. **Twinrix** contains traces of neomycin. The vaccine should not be used in subjects with known hypersensitivity to neomycin.
Indication Information
**Indications** **Twinrix** is indicated for use in non-immune adults and children aged from 1 year upwards, who are at risk of both hepatitis A and hepatitis B infection.